Curated News
By: NewsRamp Editorial Staff
October 29, 2025
NanoViricides' NV-387 Shows Breakthrough Anti-Measles Activity
TLDR
- NanoViricides' NV-387 offers first-mover advantage as the only potential Measles treatment, positioning the company for emergency FDA approvals and market leadership.
- NV-387 demonstrated 130% survival extension and lung tissue protection in humanized animal models, completing Phase I trials with no adverse events before advancing to Phase II for MPox.
- This breakthrough could save lives by providing the first effective Measles treatment and addressing multiple viral threats through broad-spectrum antiviral technology.
- NanoViricides' nanoviricide technology represents a novel approach to antiviral therapy, showing remarkable effectiveness against Measles where no treatments currently exist.
Impact - Why it Matters
This development represents a potential breakthrough in treating Measles, a highly contagious disease that has seen resurgences globally despite vaccination efforts. With no currently approved treatments available, NV-387's demonstrated effectiveness in protecting lung tissue and extending survival by 130% in severe infection models could address a critical unmet medical need. The broad-spectrum nature of this antiviral candidate suggests it might also be effective against other respiratory viruses, potentially offering a versatile therapeutic option for future outbreaks. For public health systems, this could mean new tools to combat Measles outbreaks that still cause approximately 140,000 deaths annually worldwide, particularly in regions with limited vaccination coverage. The advancement also signals progress in nanomedicine approaches to viral infections, potentially opening new treatment paradigms beyond traditional antiviral medications.
Summary
NanoViricides, Inc. (NYSE American: NNVC) has announced significant progress in its antiviral research program, with CEO Dr. Anil Diwan revealing breakthrough findings during a video interview with Proactive. The company's lead candidate, NV-387, demonstrated remarkable anti-Measles activity in both cell culture studies and humanized animal models, showing a 130% extension in survival and protection of lung tissue during severe infection stages. This development is particularly noteworthy given the current absence of approved Measles treatments globally. NV-387 has already completed Phase I human trials with no reportable adverse events and is now advancing to Phase II trials for MPox treatment. The company stands ready to support FDA emergency use applications and investigator-initiated Investigational New Drug applications for urgent Measles cases, positioning itself as a potential leader in antiviral therapeutics.
The company operates as a clinical-stage biopharmaceutical firm creating special purpose nanomaterials for antiviral therapy through its innovative nanoviricide technology platform. This technology is based on intellectual property licensed from TheraCour Pharma, Inc., with whom NanoViricides has established a comprehensive Memorandum of Understanding for developing drugs against various viral infections. Beyond Measles and MPox, the company is actively developing NV-387 as a broad-spectrum antiviral targeting multiple respiratory viruses including RSV, COVID-19, Long COVID, and Influenza. Another advanced candidate, NV-HHV-1, is being developed for Shingles treatment. The company's extensive pipeline also includes programs targeting herpes viruses, various influenza strains, HIV, Hepatitis C, and other significant viral threats, demonstrating the versatility of their platform technology.
NanoViricides maintains a robust intellectual property position with worldwide exclusive perpetual licenses for numerous viral diseases through its relationship with TheraCour. The company's business model focuses on licensing specific technology applications for targeted viruses, a strategy established since its foundation in 2005. While the path to drug approval remains lengthy and capital-intensive, the recent Measles breakthrough represents a significant milestone in the company's development trajectory. The news was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio that provides comprehensive distribution services across multiple channels including wire services, editorial syndication, and social media networks, ensuring broad visibility for this important scientific advancement.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides' NV-387 Shows Breakthrough Anti-Measles Activity
